A high proportion of Marshallese, or Marshall Islanders, living on the mainland Unites States, have undiagnosed hypertension and type 2 diabetes (T2D), according to findings that will be used to address disparities in Native Hawaiian and Pacific Islander populations.
A study of Marshall Islanders living in Arkansas and Oklahoma participating in a Diabetes Prevention Program showed a high proportion of undiagnosed hypertension and type 2 diabetes (T2D).
With 10,000 residents, Arkansas has the largest population of Marshallese in the continental United States. With hypertension and T2D disproportionately affecting minorities—including Native Hawaiian and Pacific Islander (NHPI) populations and Marshallese in particular—researchers from the University of Arkansas sought to examine the prevalence of both diagnosed and undiagnosed hypertension and T2D in the Marshallese population.
The study, in the Yale Journal of Biology and Medicine, of 378 overweight/obese Marshallese Pacific Islander adults found that 68.4% with blood readings indicative of hypertension were undiagnosed. Among participants with glycated hemoglobin (HbA1c) levels indicative of T2D, 31.6% were undiagnosed.
The study also found that that undiagnosed hypertension was significantly associated with age (P <.001) and sex (P = .028), but not with foregone health care due to cost, health insurance coverage, or body mass index (BMI).
Undiagnosed T2D was significantly associated with age (P <.05), foregone care due to cost (P = .018), health insurance status (P = .035), and BMI (P = .001) but not sex.
Among those with blood pressure readings indicative of hypertension, young adults aged 18 to 34 years were more than 3 times as likely to be undiagnosed as middle-aged adults aged 35 to 54 and 18 times as likely to be undiagnosed as older adults age 55 and older. Middle-aged adults were 5 times as likely to be undiagnosed as older adults and males were twice as likely to be undiagnosed as females.
Among those with HbA1c readings indicative of T2D, young adults had statistically equal odds of being undiagnosed as middle-aged adults (odds ratio [OR], 1.67; 95% CI, 0.61-4.95) but were over 5 times as likely to be undiagnosed as older adults (OR, 5.50; 95% CI, 1.54- 19.58). Middle-aged adults were over 3 times as likely to be undiagnosed as older adults (OR, 3.29; 95% CI, 1.20-9.01).
Participants who were unable to receive health care due to cost were less than half as likely to be undiagnosed as those who had no cost barrier to care (OR, 0.39; 95% CI, 0.18- 0.85). Uninsured participants were more than twice as likely to be undiagnosed as those with insurance (OR, 2.31; 95% CI, 1.06-5.04).
Participants who were obese were more than 5 times as likely to be undiagnosed as those who were overweight (OR; 5.51; 95% CI, 2.05-14.79).
Findings suggested the need for outreach to Marshallese to seek healthcare.
Previous studies have shown Marshallese to be hindered by language barriers, lack of understanding how to navigate the healthcare system, and concerns about being stigmatized. They also had been excluded from Medicaid, but coverage was reinstated as part of the December 2020 pandemic relief bill.
Across the United States, over 100 million (46.0%) adults aged 20 and older have hypertension, with rates even higher among minorities, leaving them vulnerable to cardiovascular disease, heart attack, stroke, and aneurysm. The 2011-2014 National Health and Nutrition Examination Survey showed 15.9% of US adults were undiagnosed. Percentages were higher for non-Hispanic Asians (24.7%) and Hispanics (20.2%) than non-Hispanic whites (14.9%). Minorities also have higher rates of T2D.
Reference
McElfish PA, Scott AJ, Chatrathi HE, et al. Undiagnosed hypertension and undiagnosed type 2 diabetes among overweight and obese Marshallese participants in a diabetes prevention program. Yale J Biol Med. 2021;94(1):5-12. Published online March 31, 2021.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More